Syndax Pharmaceuticals, Inc. (SNDX) saw its loss widen to $10.82 million, or $0.59 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $5.26 million, or $105.57 a share.
Revenue during the quarter was stable at $0.30 million, when compared with the previous year period.
Operating loss for the quarter was $11.14 million, compared with an operating loss of $4.68 million in the previous year period.
"We're pleased to report that the melanoma cohort of ENCORE 601 has met the pre-specified objective response threshold to advance into the second stage of the phase 2 trial and will re-open enrollment immediately," said Briggs W. Morrison, M.D., chief executive officer of Syndax.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]